Is there an association between peripheral immune markers and structural/functional neuroimaging findings?

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 48, Issue , 2014, Pages 295-303

  Frodl, Thomas ^a,b,c   Amico, Francesco ^a  

^a TRINITY COLLEGE DUBLIN   (Ireland)

^b ADELAIDE AND MEATH HOSPITAL   (Ireland)

^c ST JAMES S HOSPITAL   (Ireland)

Author keywords

Aging; Alzheimer's disease; Inflammation; Major depression; MRI; Schizophrenia

Indexed keywords

AGE; AGING; ALZHEIMER DISEASE; BRAIN DEVELOPMENT; CLINICAL RESEARCH; COGNITIVE DEFECT; DISEASE ASSOCIATION; DISEASE MARKER; ENVIRONMENT; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HUMAN; INFLAMMATION; MAJOR DEPRESSION; MOUSE; NEUROIMAGING; NONHUMAN; PREGNANCY; PRIMATE; REVIEW; SCHIZOPHRENIA; STRESS;

(11)C-(R)-PK11195; (R)-N-(11)C-METHYL-N-(1-METHYLPROPYL)-1-(2-CHLOROPHENYL) ISOQUINOLINE-3-CARBOXAMIDE ((11)C-(R)-PK11195); ACC; AD; AGING; AI; ALZHEIMER'S DISEASE; ANTERIOR CINGULATE CORTEX; ANTERIOR INSULA; BASAL GANGLIA; BG; C-REACTIVE PROTEIN; CA; CA3; CA4; CC; CENTRAL NERVOUS SYSTEM; CEREBROSPINAL FLUID; CINGULATE CORTEX; CNS; CORNU AMMONIS; CORNU AMMONIS REGION 3; CORNU AMMONIS REGION 4; CRP; CSF; CYTOKINE-INDUCIBLE NITRIC OXIDE SYNTHASE; DACC; DIFFUSION TENSOR IMAGING; DORSAL ANTERIOR CINGULATE CORTEX; DTI; ENDOTHELIAL VASCULAR CELL ADHESION MOLECULE-1; FA; FMRI; FRACTIONAL ANISOTROPY; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GAD; GILZ; GLUCOCORTICOID-INDUCED LEUCINE ZIPPER; GLUTAMIC ACID DECARBOXYLASE; GM; GMV; GRAY MATTER; GRAY MATTER VOLUME; HPA; HYPOTHALAMIC-PITUITARY-ADRENAL AXIS; IGG; IL-1; IL-10; IL-12; IL-1Β; IL-6; IL-8; IMMUNOGLOBULIN-G; INFLAMMATION; INOS; INTERLEUKIN-1; INTERLEUKIN-10; INTERLEUKIN-12; INTERLEUKIN-1Β; INTERLEUKIN-6; INTERLEUKIN-8; LIPOPOLYSACCHARIDE; LONG-TERM POTENTIATION; LPS; LTP; M-CSF; MACROPHAGE COLONY-STIMULATING FACTOR; MACROPHAGE INFLAMMATORY PEPTIDE-1ALPHA; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY; MAJOR DEPRESSION; MAJOR DEPRESSIVE DISORDER; MCI; MCP-1; MDD; MICRO-SIZED PARTICLES OF IRON OXIDE; MILD COGNITIVE IMPAIRMENT; MIP-1; MONOCYTE CHEMO-ATTRACTANT PROTEIN-1; MPIO; MR SPECTROSCOPY; MRI; N-METHYL-D-ASPARTATE; NITRIC OXIDE; NMDA; NO; OFC; OMPFC; ORBITO MEDIAL PREFRONTAL CORTEX; ORBITOFRONTAL CORTEX; PFC; PREFRONTAL CORTEX; PRO-IL-1Β; PRO-INTERLEUKIN-1BETA; SACC; SCHIZOPHRENIA; SERUM AND GLUCOCORTICOID-INDUCED KINASE; SGK; SIL-4R; SOLUBLE INTERLEUKIN-4 RECEPTOR; SUBGENUAL ANTERIOR CINGULATE CORTEX; VBM; VCAM-1; VOXEL-BASED MORPHOMETRY; WHITE MATTER; WHITE MATTER HYPERINTENSITY; WHITE MATTER VOLUME; WM; WMH; WMV;

ALZHEIMER DISEASE; BRAIN; DEPRESSIVE DISORDER; HUMANS; MENTAL DISORDERS; MILD COGNITIVE IMPAIRMENT; NEUROIMAGING; SCHIZOPHRENIA;

EID: 84889097583     PISSN: 02785846     EISSN: 18784216     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2012.12.013     Document Type: Review

References (118)

1. Akhtar M.W., Sunico C.R., et al. Redox regulation of protein function via cysteine S-nitrosylation and its relevance to neurodegenerative diseases. Int J Cell Biol 2012, 2012:463756.
2. Allan S.M., Pinteaux E. The interleukin-1 system: an attractive and viable therapeutic target in neurodegenerative disease. Curr Drug Targets CNS Neurol Disord 2003, 2(5):293-302.
3. Atlas S.W., Mark A.S., et al. Intracranial hemorrhage: gradient-echo MR imaging at 1.5T. Comparison with spin-echo imaging and clinical applications. Radiology 1988, 168(3):803-807.
4. Barger S.W., Harmon A.D. Microglial activation by Alzheimer amyloid precursor protein and modulation by apolipoprotein E. Nature 1997, 388(6645):878-881.
5. Baune B.T., Ponath G., et al. Association between cytokines and cerebral MRI changes in the aging brain. J Geriatr Psychiatry Neurol 2009, 22(1):23-34.
6. Beaulieu C. The basis of anisotropic water diffusion in the nervous system-a technical review. NMR Biomed 2002, 15(7-8):435-455.
7. Bettcher B.M., Wilheim R., et al. C-reactive protein is related to memory and medial temporal brain volume in older adults. Brain Behav Immun 2012, 26(1):103-108.
8. Braakman H.M., Moers-Hornikx V.M., et al. Pearls & Oy-sters: electroconvulsive therapy in anti-NMDA receptor encephalitis. Neurology 2010, 75(10):e44-e46.
9. Brown G.C. Mechanisms of inflammatory neurodegeneration: iNOS and NADPH oxidase. Biochem Soc Trans 2007, 35(Pt 5):1119-1121.
10. Brown G.C., Neher J.J. Inflammatory neurodegeneration and mechanisms of microglial killing of neurons. Mol Neurobiol 2010, 41(2-3):242-247.
11. Capuron L., Miller A.H. Immune system to brain signaling: neuropsychopharmacological implications. Pharmacol Ther 2011, 130(2):226-238.
12. Chetelat G., Baron J.C. Early diagnosis of Alzheimer's disease: contribution of structural neuroimaging. Neuroimage 2003, 18(2):525-541.
13. Cisler J.M., James G.A., et al. Differential functional connectivity within an emotion regulation neural network among individuals resilient and susceptible to the depressogenic effects of early life stress. Psychol Med 2012, 1-12.
14. Cuingnet R., Gerardin E., et al. Automatic classification of patients with Alzheimer's disease from structural MRI: a comparison of ten methods using the ADNI database. Neuroimage 2011, 56(2):766-781.
15. Dalmau J., Tuzun E., et al. Paraneoplastic anti-N-methyl-d-aspartate receptor encephalitis associated with ovarian teratoma. Ann Neurol 2007, 61(1):25-36.
16. Dalmau J., Gleichman A.J., et al. Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies. Lancet Neurol 2008, 7(12):1091-1098.
17. Dantzer R., O'Connor J.C., et al. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci 2008, 9(1):46-56.
18. Davatzikos C., Bhatt P., et al. Prediction of MCI to AD conversion, via MRI, CSF biomarkers, and pattern classification. Neurobiol Aging 2011, 32(12):2322. [e2319-2327].
19. De La Garza R. Endotoxin- or pro-inflammatory cytokine-induced sickness behavior as an animal model of depression: focus on anhedonia. Neurosci Biobehav Rev 2005, 29(4-5):761-770.
20. Doorduin J., de Vries E.F., et al. Neuroinflammation in schizophrenia-related psychosis: a PET study. J Nucl Med 2009, 50(11):1801-1807.
21. Duman R.S. Pathophysiology of depression: the concept of synaptic plasticity. Eur Psychiatry 2002, 17(Suppl. 3):306-310.
22. Eisenberger N.I., Inagaki T.K., et al. An fMRI study of cytokine-induced depressed mood and social pain: the role of sex differences. Neuroimage 2009, 47(3):881-890.
23. Eisenberger N.I., Berkman E.T., et al. Inflammation-induced anhedonia: endotoxin reduces ventral striatum responses to reward. Biol Psychiatry 2010, 68(8):748-754.
24. Ewers M., Walsh C., et al. Prediction of conversion from mild cognitive impairment to Alzheimer's disease dementia based upon biomarkers and neuropsychological test performance. Neurobiol Aging 2012, 33(7):1203-1214.
25. Forlenza O.V., Diniz B.S., et al. Increased serum IL-1beta level in Alzheimer's disease and mild cognitive impairment. Dement Geriatr Cogn Disord 2009, 28(6):507-512.
26. Forrest C.M., Mackay G.M., et al. Tryptophan loading induces oxidative stress. Free Radic Res 2004, 38(11):1167-1171.
27. Frodl T., Carballedo A., et al. Reduced expression of glucocorticoid-inducible genes GILZ and SGK-1: high IL-6 levels are associated with reduced hippocampal volumes in major depressive disorder. Transl Psychiatry 2012, 2:e88.
28. Furney S.J., Kronenberg D., et al. Combinatorial markers of mild cognitive impairment conversion to Alzheimer's disease-cytokines and MRI measures together predict disease progression. J Alzheimers Dis 2011, 26(Suppl. 3):395-405.
29. Giovannini M.G., Scali C., et al. Experimental brain inflammation and neurodegeneration as model of Alzheimer's disease: protective effects of selective COX-2 inhibitors. Int J Immunopathol Pharmacol 2003, 16(2 Suppl.):31-40.
30. Glantz L.A., Lewis D.A. Dendritic spine density in schizophrenia and depression. Arch Gen Psychiatry 2001, 58(2):203.
31. Gunstad J., Bausserman L., et al. C-reactive protein, but not homocysteine, is related to cognitive dysfunction in older adults with cardiovascular disease. J Clin Neurosci 2006, 13(5):540-546.
32. Hampel H., Haslinger A., et al. Pattern of interleukin-6 receptor complex immunoreactivity between cortical regions of rapid autopsy normal and Alzheimer's disease brain. Eur Arch Psychiatry Clin Neurosci 2005, 255(4):269-278.
33. Hampel H., Burger K., et al. Core candidate neurochemical and imaging biomarkers of Alzheimer's disease. Alzheimers Dement 2008, 4(1):38-48.
34. Hampel H., Frank R., et al. Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives. Nat Rev Drug Discov 2010, 9(7):560-574.
35. Harrison N.A., Brydon L., et al. Inflammation causes mood changes through alterations in subgenual cingulate activity and mesolimbic connectivity. Biol Psychiatry 2009, 66(5):407-414.
36. Hauss-Wegrzyniak B., Galons J.P., et al. Quantitative volumetric analyses of brain magnetic resonance imaging from rat with chronic neuroinflammation. Exp Neurol 2000, 165(2):347-354.
37. Hoschl C., Hajek T. Hippocampal damage mediated by corticosteroids-a neuropsychiatric research challenge. Eur Arch Psychiatry Clin Neurosci 2001, 251(Suppl. 2):II81-II88.
38. Ikemoto S., Panksepp J. The role of nucleus accumbens dopamine in motivated behavior: a unifying interpretation with special reference to reward-seeking. Brain Res Brain Res Rev 1999, 31(1):6-41.
39. In 't Veld B.A., Launer L.J., et al. NSAIDs and incident Alzheimer's disease. The Rotterdam Study. Neurobiol Aging 1998, 19(6):607-611.
40. Irani S.R., Bera K., et al. N-methyl-d-aspartate antibody encephalitis: temporal progression of clinical and paraclinical observations in a predominantly non-paraneoplastic disorder of both sexes. Brain 2010, 133(Pt 6):1655-1667.
41. Jack C.R., Shiung M.M., et al. Brain atrophy rates predict subsequent clinical conversion in normal elderly and amnestic MCI. Neurology 2005, 65(8):1227-1231.
42. Jefferson A.L., Massaro J.M., et al. Inflammatory biomarkers are associated with total brain volume: the Framingham Heart Study. Neurology 2007, 68(13):1032-1038.
43. Jhamandas K.H., Boegman R.J., et al. Excitotoxicity of quinolinic acid: modulation by endogenous antagonists. Neurotox Res 2000, 2(2-3):139-155.
44. Khairova R.A., Machado-Vieira R., et al. A potential role for pro-inflammatory cytokines in regulating synaptic plasticity in major depressive disorder. Int J Neuropsychopharmacol 2009, 12(4):561-578.
45. Kleinig T.J., Thompson P.D., et al. The distinctive movement disorder of ovarian teratoma-associated encephalitis. Mov Disord 2008, 23(9):1256-1261.
46. Kole M.H., Czeh B., et al. Homeostatic maintenance in excitability of tree shrew hippocampal CA3 pyramidal neurons after chronic stress. Hippocampus 2004, 14(6):742-751.
47. Kolluri N., Sun Z., et al. Lamina-specific reductions in dendritic spine density in the prefrontal cortex of subjects with schizophrenia. Am J Psychiatry 2005, 162(6):1200-1202.
48. Koolschijn P.C., van Haren N.E., et al. Brain volume abnormalities in major depressive disorder: a meta-analysis of magnetic resonance imaging studies. Hum Brain Mapp 2009, 30(11):3719-3735.
49. Krishnan V., Nestler E.J. The molecular neurobiology of depression. Nature 2008, 455(7215):894-902.
50. Kullmann J.S., Grigoleit J.S., et al. Neural response to emotional stimuli during experimental human endotoxemia. Hum Brain Mapp 2012, http://dx.doi.org/10.1002/hbm.22063 [Mar 28, Electronic publication ahead of print].
51. Lammers C.H., Garcia-Borreguero D., et al. Combined dexamethasone/corticotropin-releasing hormone test in patients with schizophrenia and in normal controls: II. Biol Psychiatry 1995, 38(12):803-807.
52. Leonard B.E., Schwarz M., et al. The metabolic syndrome in schizophrenia: is inflammation a contributing cause?. J Psychopharmacol 2012, 26(5 Suppl.):33-41.
53. Li Q., Cheung C., et al. Voxel-based analysis of postnatal white matter microstructure in mice exposed to immune challenge in early or late pregnancy. Neuroimage 2010, 52(1):1-8.
54. Lin H.B., Yang X.M., et al. Memory deficits and neurochemical changes induced by C-reactive protein in rats: implication in Alzheimer's disease. Psychopharmacology (Berl) 2009, 204(4):705-714.
55. Lue L.F., Rydel R., et al. Inflammatory repertoire of Alzheimer's disease and nondemented elderly microglia in vitro. Glia 2001, 35(1):72-79.
56. Macqueen G., Frodl T. The hippocampus in major depression: evidence for the convergence of the bench and bedside in psychiatric research?. Mol Psychiatry 2011, 16(3):252-264. [Mar].
57. Magarinos A.M., McEwen B.S., et al. Chronic psychosocial stress causes apical dendritic atrophy of hippocampal CA3 pyramidal neurons in subordinate tree shrews. J Neurosci 1996, 16(10):3534-3540.
58. Mansur R.B., Zugman A., et al. Cytokines in schizophrenia: possible role of anti-inflammatory medications in clinical and preclinical stages. Psychiatry Clin Neurosci 2012, 66(4):247-260.
59. Marsland A.L., Gianaros P.J., et al. Interleukin-6 covaries inversely with hippocampal grey matter volume in middle-aged adults. Biol Psychiatry 2008, 64(6):484-490.
60. Matsumoto Y., Yanase D., et al. Cerebrospinal fluid/serum IgG index is correlated with medial temporal lobe atrophy in Alzheimer's disease. Dement Geriatr Cogn Disord 2008, 25(2):144-147.
61. McAteer M.A., Sibson N.R., et al. In vivo magnetic resonance imaging of acute brain inflammation using microparticles of iron oxide. Nat Med 2007, 13(10):1253-1258.
62. McGeer P.L., McGeer E.G. The inflammatory response system of brain: implications for therapy of Alzheimer and other neurodegenerative diseases. Brain Res Brain Res Rev 1995, 21(2):195-218.
63. McKinnon M.C., Yucel K., et al. A meta-analysis examining clinical predictors of hippocampal volume in patients with major depressive disorder. J Psychiatry Neurosci 2009, 34(1):41-54.
64. McNally L., Bhagwagar Z., et al. Inflammation, glutamate, and glia in depression: a literature review. CNS Spectr 2008, 13(6):501-510.
65. Miller A.H., Maletic V., et al. Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol Psychiatry 2009, 65(9):732-741.
66. Mondelli V., Pariante C.M., et al. Higher cortisol levels are associated with smaller left hippocampal volume in first-episode psychosis. Schizophr Res 2010, 119(1-3):75-78.
67. Monji A. The neuroinflammation hypothesis of psychiatric disorders. Seishin Shinkeigaku Zasshi 2012, 114(2):124-133.
68. Montagne A., Gauberti M., Macrez R., Jullienne A., Briens A., Raynaud J.S., et al. Ultra-sensitive molecular MRI of cerebrovascular cell activation enables early detection of chronic central nervous system disorders. Neuroimage 2012, 63(2):760-770. [Nov 1].
69. Muller N., Myint A.M., et al. Inflammation in schizophrenia. Adv Protein Chem Struct Biol 2012, 88:49-68.
70. Murray C.A., Lynch M.A. Evidence that increased hippocampal expression of the cytokine interleukin-1 beta is a common trigger for age- and stress-induced impairments in long-term potentiation. J Neurosci 1998, 18(8):2974-2981.
71. Myint A.M., Schwarz M.J., et al. The role of the kynurenine metabolism in major depression. J Neural Transm 2012, 119(2):245-251.
72. Nestler E.J., Carlezon W.A. The mesolimbic dopamine reward circuit in depression. Biol Psychiatry 2006, 59(12):1151-1159.
73. Noble J.M., Manly J.J., et al. Association of C-reactive protein with cognitive impairment. Arch Neurol 2010, 67(1):87-92.
74. Nokura K., Yamamoto H., et al. Reversible limbic encephalitis caused by ovarian teratoma. Acta Neurol Scand 1997, 95(6):367-373.
75. Okamura H., Oomori N., et al. An acutely confused 15-year-old girl. Lancet 1997, 350(9076):488.
76. Oxenkrug G. Antioxidant effects of N-acetylserotonin: possible mechanisms and clinical implications. Ann N Y Acad Sci 2005, 1053:334-347.
77. Oxenkrug G.F. Genetic and hormonal regulation of tryptophan kynurenine metabolism: implications for vascular cognitive impairment, major depressive disorder, and aging. Ann N Y Acad Sci 2007, 1122:35-49.
78. Pantelis C., Velakoulis D., et al. Neuroanatomical abnormalities before and after onset of psychosis: a cross-sectional and longitudinal MRI comparison. Lancet 2003, 361(9354):281-288.
79. Parthasarathi U.D., Harrower T., et al. Psychiatric presentation of voltage-gated potassium channel antibody-associated encephalopathy. Case report. Br J Psychiatry 2006, 189:182-183.
80. Perez-Severiano F., Escalante B., et al. Nitric oxide synthase inhibition prevents acute quinolinate-induced striatal neurotoxicity. Neurochem Res 1998, 23(10):1297-1302.
81. Ray S., Britschgi M., et al. Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins. Nat Med 2007, 13(11):1359-1362.
82. Raz N., Yang Y., et al. Volume of white matter hyperintensities in healthy adults: contribution of age, vascular risk factors, and inflammation-related genetic variants. Biochim Biophys Acta 2012, 1822(3):361-369.
83. Reichenberg A., Yirmiya R., et al. Cytokine-associated emotional and cognitive disturbances in humans. Arch Gen Psychiatry 2001, 58(5):445-452.
84. Ressler K.J., Nemeroff C.B. Role of serotonergic and noradrenergic systems in the pathophysiology of depression and anxiety disorders. Depress Anxiety 2000, 12(Suppl. 1):2-19.
85. Ryu J.K., Choi H.B., et al. Combined minocycline plus pyruvate treatment enhances effects of each agent to inhibit inflammation, oxidative damage, and neuronal loss in an excitotoxic animal model of Huntington's disease. Neuroscience 2006, 141(4):1835-1848.
86. Santarelli L., Saxe M., et al. Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science 2003, 301(5634):805-809.
87. Sapolsky R.M., Krey L.C., et al. The neuroendocrinology of stress and aging: the glucocorticoid cascade hypothesis. Endocr Rev 1986, 7(3):284-301.
88. Satizabal C.L., Zhu Y.C., et al. Circulating IL-6 and CRP are associated with MRI findings in the elderly: the 3C-Dijon Study. Neurology 2012, 78(10):720-727.
89. Schrag M., McAuley G., et al. Correlation of hypointensities in susceptibility-weighted images to tissue histology in dementia patients with cerebral amyloid angiopathy: a postmortem MRI study. Acta Neuropathol 2010, 119(3):291-302.
90. Semmler A., Okulla T., et al. Systemic inflammation induces apoptosis with variable vulnerability of different brain regions. J Chem Neuroanat 2005, 30(2-3):144-157.
91. Slavich G.M., Way B.M., et al. Neural sensitivity to social rejection is associated with inflammatory responses to social stress. Proc Natl Acad Sci U S A 2010, 107(33):14817-14822.
92. Sloane J.A., Hollander W., et al. Increased microglial activation and protein nitration in white matter of the aging monkey. Neurobiol Aging 1999, 20(4):395-405.
93. Stone J.M., Day F., et al. Glutamate dysfunction in people with prodromal symptoms of psychosis: relationship to gray matter volume. Biol Psychiatry 2009, 66(6):533-539.
94. Strauss S., Bauer J., et al. Detection of interleukin-6 and alpha 2-macroglobulin immunoreactivity in cortex and hippocampus of Alzheimer's disease patients. Lab Invest 1992, 66(2):223-230.
95. Sweet R.A., Henteleff R.A., et al. Reduced dendritic spine density in auditory cortex of subjects with schizophrenia. Neuropsychopharmacology 2009, 34(2):374-389.
96. Taki Y., Thyreau B., et al. Correlation between high-sensitivity C-reactive protein and brain gray matter volume in healthy elderly subjects. Hum Brain Mapp 2012, http://dx.doi.org/10.1002/hbm.22073 [Mar 22, Electronic publication ahead of print].
97. Tan J., Town T., et al. Microglial activation resulting from CD40-CD40L interaction after beta-amyloid stimulation. Science 1999, 286(5448):2352-2355.
98. Tan Z.S., Beiser A.S., et al. Inflammatory markers and the risk of Alzheimer disease: the Framingham Study. Neurology 2007, 68(22):1902-1908.
99. Terrando N., Rei Fidalgo A., et al. The impact of IL-1 modulation on the development of lipopolysaccharide-induced cognitive dysfunction. Crit Care 2010, 14(3):R88.
100. Teunissen C.E., van Boxtel M.P., et al. Inflammation markers in relation to cognition in a healthy aging population. J Neuroimmunol 2003, 134(1-2):142-150.
101. Thomas S.R., Stocker R. Redox reactions related to indoleamine 2,3-dioxygenase and tryptophan metabolism along the kynurenine pathway. Redox Rep 1999, 4(5):199-220.
102. van Berckel B.N., Bossong M.G., et al. Microglia activation in recent-onset schizophrenia: a quantitative (R)-[11C]PK11195 positron emission tomography study. Biol Psychiatry 2008, 64(9):820-822.
103. Vandenabeele P., Fiers W. Is amyloidogenesis during Alzheimer's disease due to an IL-1-/IL-6-mediated 'acute phase response' in the brain?. Immunol Today 1991, 12(7):217-219.
104. Vincent A., Buckley C., et al. Potassium channel antibody-associated encephalopathy: a potentially immunotherapy-responsive form of limbic encephalitis. Brain 2004, 127(Pt 3):701-712.
105. von Zur Muhlen C., Sibson N.R., et al. A contrast agent recognizing activated platelets reveals murine cerebral malaria pathology undetectable by conventional MRI. J Clin Invest 2008, 118(3):1198-1207.
106. Walther K., Bendlin B.B., et al. Anti-inflammatory drugs reduce age-related decreases in brain volume in cognitively normal older adults. Neurobiol Aging 2011, 32(3):497-505.
107. Wang J., Dunn A.J. The role of interleukin-6 in the activation of the hypothalamo-pituitary-adrenocortical axis and brain indoleamines by endotoxin and interleukin-1 beta. Brain Res 1999, 815(2):337-348.
108. Wellman C.L. Dendritic reorganization in pyramidal neurons in medial prefrontal cortex after chronic corticosterone administration. J Neurobiol 2001, 49(3):245-253.
109. Wersching H., Duning T., et al. Serum C-reactive protein is linked to cerebral microstructural integrity and cognitive function. Neurology 2010, 74(13):1022-1029.
110. Willette A.A., Lubach G.R., et al. Brain enlargement and increased behavioral and cytokine reactivity in infant monkeys following acute prenatal endotoxemia. Behav Brain Res 2011, 219(1):108-115.
111. Wohleb E.S., Hanke M.L., et al. beta-Adrenergic receptor antagonism prevents anxiety-like behavior and microglial reactivity induced by repeated social defeat. J Neurosci 2011, 31(17):6277-6288.
112. Woolley C.S., Gould E., et al. Naturally occurring fluctuation in dendritic spine density on adult hippocampal pyramidal neurons. J Neurosci 1990, 10(12):4035-4039.
113. Wright I.C., Rabe-Hesketh S., et al. Meta-analysis of regional brain volumes in schizophrenia. Am J Psychiatry 2000, 157(1):16-25.
114. Wright C.E., Strike P.C., et al. Acute inflammation and negative mood: mediation by cytokine activation. Brain Behav Immun 2005, 19(4):345-350.
115. Wuerfel J., Haertle M., et al. Perivascular spaces-MRI marker of inflammatory activity in the brain?. Brain 2008, 131(Pt 9):2332-2340.
116. Yaffe K., Lindquist K., et al. Inflammatory markers and cognition in well-functioning African-American and white elders. Neurology 2003, 61(1):76-80.
117. Zandi M.S., Irani S.R., et al. Disease-relevant autoantibodies in first episode schizophrenia. J Neurol 2011, 258(4):686-688.
118. Zuliani G., Cavalieri M., et al. Markers of endothelial dysfunction in older subjects with late onset Alzheimer's disease or vascular dementia. J Neurol Sci 2008, 272(1-2):164-170.